DAY ONE BIOPHARMACEUTICALS I (DAWN) Fundamental Analysis & Valuation

NASDAQ:DAWN • US23954D1090

Current stock price

21.46 USD
0 (0%)
At close:
21.45 USD
-0.01 (-0.05%)
After Hours:

This DAWN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. DAWN Profitability Analysis

1.1 Basic Checks

  • In the past year DAWN has reported negative net income.
  • In the past year DAWN has reported a negative cash flow from operations.
  • In the past 5 years DAWN always reported negative net income.
  • In the past 5 years DAWN always reported negative operating cash flow.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • With a decent Return On Assets value of -21.13%, DAWN is doing good in the industry, outperforming 75.24% of the companies in the same industry.
  • DAWN has a Return On Equity of -24.33%. This is in the better half of the industry: DAWN outperforms 79.11% of its industry peers.
Industry RankSector Rank
ROA -21.13%
ROE -24.33%
ROIC N/A
ROA(3y)-29.25%
ROA(5y)-37.47%
ROE(3y)-32.61%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Gross Margin of DAWN (89.12%) is better than 90.72% of its industry peers.
  • DAWN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. DAWN Health Analysis

2.1 Basic Checks

  • DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for DAWN has been increased compared to 1 year ago.
  • DAWN has more shares outstanding than it did 5 years ago.
  • DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 18.61 indicates that DAWN is not in any danger for bankruptcy at the moment.
  • DAWN's Altman-Z score of 18.61 is amongst the best of the industry. DAWN outperforms 87.62% of its industry peers.
  • DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.61
ROIC/WACCN/A
WACC9.2%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 8.02 indicates that DAWN has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 8.02, DAWN is doing good in the industry, outperforming 71.18% of the companies in the same industry.
  • DAWN has a Quick Ratio of 7.91. This indicates that DAWN is financially healthy and has no problem in meeting its short term obligations.
  • DAWN's Quick ratio of 7.91 is fine compared to the rest of the industry. DAWN outperforms 71.18% of its industry peers.
Industry RankSector Rank
Current Ratio 8.02
Quick Ratio 7.91
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DAWN Growth Analysis

3.1 Past

  • DAWN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.57%, which is quite impressive.
  • The Revenue has grown by 20.60% in the past year. This is a very strong growth!
EPS 1Y (TTM)41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.19%
Revenue 1Y (TTM)20.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.97%

3.2 Future

  • Based on estimates for the next years, DAWN will show a very strong growth in Earnings Per Share. The EPS will grow by 31.19% on average per year.
  • Based on estimates for the next years, DAWN will show a very strong growth in Revenue. The Revenue will grow by 32.96% on average per year.
EPS Next Y23.71%
EPS Next 2Y39.63%
EPS Next 3Y34.92%
EPS Next 5Y31.19%
Revenue Next Year56.78%
Revenue Next 2Y41.73%
Revenue Next 3Y37.51%
Revenue Next 5Y32.96%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. DAWN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DAWN. In the last year negative earnings were reported.
  • Also next year DAWN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

  • DAWN's earnings are expected to grow with 34.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.63%
EPS Next 3Y34.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DAWN Dividend Analysis

5.1 Amount

  • No dividends for DAWN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DAWN Fundamentals: All Metrics, Ratios and Statistics

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (4/7/2026, 5:20:00 PM)

After market: 21.45 -0.01 (-0.05%)

21.46

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-01
Inst Owners77.97%
Inst Owner Change0%
Ins Owners2.41%
Ins Owner Change0.38%
Market Cap2.22B
Revenue(TTM)158.18M
Net Income(TTM)-107.32M
Analysts52.31
Price Target21.17 (-1.35%)
Short Float %9.65%
Short Ratio1.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.41%
Min EPS beat(2)-35.56%
Max EPS beat(2)36.38%
EPS beat(4)3
Avg EPS beat(4)10.9%
Min EPS beat(4)-35.56%
Max EPS beat(4)36.38%
EPS beat(8)5
Avg EPS beat(8)8.61%
EPS beat(12)8
Avg EPS beat(12)6.48%
EPS beat(16)10
Avg EPS beat(16)2.54%
Revenue beat(2)2
Avg Revenue beat(2)5.29%
Min Revenue beat(2)2.13%
Max Revenue beat(2)8.44%
Revenue beat(4)2
Avg Revenue beat(4)1.12%
Min Revenue beat(4)-5.83%
Max Revenue beat(4)8.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.27%
PT rev (3m)-6.74%
EPS NQ rev (1m)-0.34%
EPS NQ rev (3m)9.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.68%
Revenue NQ rev (1m)-1.05%
Revenue NQ rev (3m)6.82%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)7.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.01
P/FCF N/A
P/OCF N/A
P/B 5.02
P/tB 5.24
EV/EBITDA N/A
EPS(TTM)-1.04
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS1.53
BVpS4.27
TBVpS4.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.13%
ROE -24.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.12%
FCFM N/A
ROA(3y)-29.25%
ROA(5y)-37.47%
ROE(3y)-32.61%
ROE(5y)-40.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.9%
Cap/Sales 2.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.02
Quick Ratio 7.91
Altman-Z 18.61
F-Score4
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)655.24%
Cap/Depr(5y)403.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.19%
EPS Next Y23.71%
EPS Next 2Y39.63%
EPS Next 3Y34.92%
EPS Next 5Y31.19%
Revenue 1Y (TTM)20.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%83.97%
Revenue Next Year56.78%
Revenue Next 2Y41.73%
Revenue Next 3Y37.51%
Revenue Next 5Y32.96%
EBIT growth 1Y41.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.83%
OCF growth 3YN/A
OCF growth 5YN/A

DAY ONE BIOPHARMACEUTICALS I / DAWN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DAY ONE BIOPHARMACEUTICALS I?

ChartMill assigns a fundamental rating of 4 / 10 to DAWN.


What is the valuation status for DAWN stock?

ChartMill assigns a valuation rating of 1 / 10 to DAY ONE BIOPHARMACEUTICALS I (DAWN). This can be considered as Overvalued.


How profitable is DAY ONE BIOPHARMACEUTICALS I (DAWN) stock?

DAY ONE BIOPHARMACEUTICALS I (DAWN) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for DAWN stock?

The Earnings per Share (EPS) of DAY ONE BIOPHARMACEUTICALS I (DAWN) is expected to grow by 23.71% in the next year.